

02 - References

References

- 918 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 13 References
1. Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. *Neuropsychiatr Dis Treat* 2009; 5:563–576.
 2. Wong A, et al. Agomelatine overdose and related toxicity. *Toxicol Commun* 2018; 2:62–65.
 3. US Food and Drug Administration. Drugs@FDA: FDA-approved drugs. 2023; <https://www.accessdata.fda.gov/scripts/cder/daf>.
 4. Buckley NA, et al. ‘Atypical’ antidepressants in overdose: clinical considerations with respect to safety. *Drug Saf* 2003; 26:539–551.
 5. Mercerolle M, et al. A fatal case of bupropion (Zyban) overdose. *J Anal Toxicol* 2008; 32:192–196.
 6. Murray B, et al. Single-agent bupropion exposures: clinical characteristics and an atypical cause of serotonin toxicity. *J Med Toxicol* 2020; 16:12–16.
 7. Overberg A, et al. Toxicity of bupropion overdose compared with selective serotonin reuptake inhibitors. *Pediatrics* 2019; 144:e20183295.
 8. Robinson S. Treatment of status epilepticus and prolonged QT after massive intentional bupropion overdose with lidocaine. *Am J Emerg Med* 2022; 55:232.e3–232.e4.
 9. Alibegović A, et al. Fatal overdose with a combination of SNRIs venlafaxine and duloxetine. *Forensic Sci Med Pathol* 2019; 15:258–261.
 10. Menchetti M, et al. Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines. *World J Biol Psychiatry* 2009; 10:385–389.
 11. White N, et al. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. *J Med Toxicol* 2008; 4:238–250.
 12. Darracq MA, et al. A retrospective review of isolated duloxetine--exposure cases. *Clin Toxicol (Phila)* 2013; 51:106–110.
 13. Scanlon KA, et al. Comprehensive duloxetine analysis in a fatal overdose. *J Anal Toxicol* 2016; 40:167–170.
 14. Janssen-Cilag Ltd. Summary of product characteristics. Spravato 28 mg nasal spray, solution. 2023; <https://www.medicines.org.uk/emc/product/10977/smpc>.
 15. Corkery JM, et al. Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997–2019. *J Psychopharmacol* 2021; 35:1324–1348.
 16. Green SM, et al. Inadvertent ketamine overdose in children: clinical manifestations and outcome. *Ann Emerg Med* 1999; 34:492–497.
 17. Cassidy S, et al. Fatal toxicity of antidepressant drugs in overdose. *BMJ* 1987; 295:1021–1024.
 18. Henry JA, et al. Relative mortality from overdose of antidepressants. *BMJ* 1995; 310:221–224.
 19. Crome P. Antidepressant overdosage. *Drugs* 1982; 23:431–461.
 20. Henry JA. Epidemiology and relative toxicity of antidepressant drugs in overdose. *Drug Saf* 1997; 16:374–390.
 21. Waring WS, et al. Acute myocarditis after massive phenelzine overdose. *Eur J Clin Pharmacol* 2007; 63:1007–1009.
 22. Chand S, et al. One hundred cases of acute intoxication with mianserin hydrochloride. *Pharmacopsychiatry* 1981; 14:15–17.
 23. Scherer D, et al. Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin. *Naunyn Schmiedebergs Arch Pharmacol* 2008; 378:73–83.
 24. Koseoglu Z, et al. Bradycardia and hypotension in mianserin

intoxication. *Hum Exp Toxicol* 2010; 29:887–888. 25. Bremner JD, et al. Safety of mirtazapine in overdose. *J Clin Psychiatry* 1998; 59:233–235. 26. LoVecchio F, et al. Outcomes after isolated mirtazapine (Remeron) supratherapeutic ingestions. *J Emerg Med* 2008; 34:77–78. 27. Berling I, et al. Mirtazapine overdose is unlikely to cause major toxicity. *Clin Toxicol (Phila)* 2014; 52:20–24. 28. Nelson JC, et al. Morbidity and mortality associated with medications used in the treatment of depression: an analysis of cases reported to U.S. Poison Control Centers, 2000–2014. *Am J Psychiatry* 2017; 174:438–450. 29. Vignali C, et al. Mirtazapine fatal poisoning. *Forensic Sci Int* 2017; 276:e8–e12. 30. Hetzel W. Safety of moclobemide taken in overdose for attempted suicide. *Psychopharmacology (Berl)* 1992; 106 Suppl:S127–S129. 31. Myrenfors PG, et al. Moclobemide overdose. *J Intern Med* 1993; 233:113–115. 32. Baldwin DS, et al. Tolerability and safety of reboxetine. *Rev Contemp Pharmacother* 2000; 11:321–330. 33. Cheeta S, et al. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000. *Br J Psychiatry* 2004; 184:41–47. 34. Barbey JT, et al. SSRI safety in overdose. *J Clin Psychiatry* 1998; 59 Suppl 15:42–48. 35. Jimmink A, et al. Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. *Ther Drug Monit* 2008; 30:365–371. 36. Tarabar AF, et al. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. *J Med Toxicol* 2008; 4:101–105. 37. Kraai EP, et al. Citalopram overdose: a fatal case. *J Med Toxicol* 2015; 11:232–236. 38. Yilmaz Z, et al. Escitalopram causes fewer seizures in human overdose than citalopram. *Clin Toxicol (Phila)* 2010; 48:207–212. 39. van Gorp F, et al. Clinical and ECG effects of escitalopram overdose. *Ann Emerg Med* 2009; 54:404–408. 40. Gamble DE, et al. Trazodone overdose: four years of experience from voluntary reports. *J Clin Psychiatry* 1986; 47:544–546. 41. Martinez MA, et al. Investigation of a fatality due to trazodone poisoning: case report and literature review. *J Anal Toxicol* 2005; 29:262–268. 42. Dattilo PB, et al. Prolonged QT associated with an overdose of trazodone. *J Clin Psychiatry* 2007; 68:1309–1310. 43. Service JA, et al. QT prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. *Clin Toxicol (Phila)* 2008; 46:71–73. 44. Caksen H, et al. Acute amitriptyline intoxication: an analysis of 44 children. *Hum Exp Toxicol* 2006; 25:107–110. 45. Howell C, et al. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. *Br J Clin Pharmacol* 2007; 64:192–197. 46. Hojer J, et al. Fatal cardiotoxicity induced by venlafaxine overdosage. *Clin Toxicol (Phila)* 2008; 46:336–337. 47. Taylor D. Venlafaxine and cardiovascular toxicity. *BMJ* 2010; 340:327.

Psychotropic drugs in special conditions CHAPTER 13 48. Bekka E, et al. Dose-related hypoglycemia in venlafaxine poisoning: a retrospective cohort study. *Clin Toxicol (Phila)* 2022; 60:1336–1344. 49. Cooper JM, et al. Desvenlafaxine overdose and the occurrence of serotonin toxicity, seizures and cardiovascular effects. *Clin Toxicol (Phila)* 2017; 55:18–24. 50. Russell JL, et al. Pediatric ingestion of vilazodone compared to other selective serotonin reuptake inhibitor medications. *Clin Toxicol (Phila)* 2017; 55:352–356. 51. Allergan USA Inc. Highlights of prescribing information: VIIBRYD (vilazodone hydrochloride) tablets for oral use. 2023; https://www.allergan.com/assets/pdf/viibryd_pi. 52. Mazza MG, et al. Vortioxetine overdose in a suicidal attempt: a case report. *Medicine (Baltimore)* 2018; 97:e10788. 53. Isbister GK, et al. Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes. *Med J Aust* 2006; 184:354–356. 54. Ward DI. Two cases of amisulpride overdose: a cause for prolonged QT syndrome. *Emerg Med Australas* 2005; 17:274–276. 55. Isbister GK, et al. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. *J Clin Psychopharmacol* 2010; 30:391–395. 56. Lofton AL, et al. Atypical experience: a case series of

pediatric aripiprazole exposures. *Clin Toxicol (Phila)* 2005; 43:151-153. 57. Carstairs SD, et al. Overdose of aripiprazole, a new type of antipsychotic. *J Emerg Med* 2005; 28:311-313. 58. Forrester MB. Aripiprazole exposures reported to Texas poison control centers during 2002-2004. *J Toxicol Environ Health A* 2006; 69:1719-1726. 59. Taylor JE, et al. A case of intentional asenapine overdose. *Prim Care Companion CNS Disord* 2013; 15:PCC.13I01547. 60. Haddad PM, et al. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. *Drugs* 2002; 62:1649-1671. 61. Levine BS, et al. Two fatalities involving haloperidol. *J Anal Toxicol* 1991; 15:282-284. 62. Henderson RA, et al. Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose. *Hum Exp Toxicol* 1991; 10:59-62. 63. Recordati Pharmaceuticals Limited. Summary of product characteristics. Reagila (cariprazine) 1.5mg, 3mg, 4.5mg and 6mg hard capsules. 2024 (last accessed August 2024); <https://www.medicines.org.uk/emc/product/9401/smpc>. 64. Trenton A, et al. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. *CNS Drugs* 2003; 17:307-324. 65. Flanagan RJ, et al. Suspected clozapine poisoning in the UK/Eire, 1992-2003. *Forensic Sci Int* 2005; 155:91-99. 66. Shigeev SV, et al. [Clozapine intoxication: theoretical aspects and forensic-medical examination]. *Sud Med Ekspert* 2013; 56:41-46. 67. Vigneault P, et al. Iloperidone (Fanapt®), a novel atypical antipsychotic, is a potent HERG blocker and delays cardiac ventricular repolarization at clinically relevant concentration. *Pharmacol Res* 2012; 66:60-65. 68. Vanda Pharmaceuticals Inc. Highlights of prescribing information: FANAPT® (iloperidone) tablets. 2021; <https://www.fanapt.com/product/pi/pdf/fanapt.pdf>. 69. Amon J, et al. A case of iloperidone overdose in a 27-year-old man with cocaine abuse. *SAGE Open Med Case Rep* 2016; 4:2050313x16660485. 70. Vyas P, et al. An evaluation of lumateperone tosylate for the treatment of schizophrenia. *Expert Opin Pharmacother* 2020; 21:139-145. 71. CNX Therapeutics Ltd (formerly Sunovion Pharmaceuticals Europe). Summary of product characteristics. Latuda 18.5mg, 37mg and 74mg film-coated tablets. 2022 (last accessed December 2023); <https://www.medicines.org.uk/emc/product/3299/smpc>. 72. Molnar GP, et al. Acute lurasidone overdose. *J Clin Psychopharmacol* 2014; 34:768-770. 73. Chue P, et al. A review of olanzapine--associated toxicity and fatality in overdose. *J Psychiatry Neurosci* 2003; 28:253-261. 74. Waring WS, et al. Olanzapine overdose is associated with acute muscle toxicity. *Hum Exp Toxicol* 2006; 25:735-740. 75. Morissette P, et al. Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. *J Psychopharmacol* 2007; 21:735-741. 76. Krka UK Ltd. Summary of product characteristics. Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 20mg tablets. 2023 (last accessed August 2024); <https://www.medicines.org.uk/emc/product/14727/smpc>. 77. Buckley NA, et al. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. *J Toxicol Clin Toxicol* 1995; 33:199-204. 78. Li C, et al. Acute pulmonary edema induced by overdosage of phenothiazines. *Chest* 1992; 101:102-104. 79. Flanagan RJ. Fatal toxicity of drugs used in psychiatry. *Hum Psychopharmacol* 2008; 23 Suppl 1:43-51. 80. Sahli ZT, et al. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis. *Exp Opin Drug Discov* 2018; 13:103-110. 81. Vanover KE, et al. Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. *J Clin Pharmacol* 2007; 47:704-714. 82. Ngo A, et al. Acute quetiapine overdose in adults: a 5-year retrospective case series. *Ann Emerg Med* 2008; 52:541-547. 83. Bertol E, et al. Overdose of quetiapine - a case report with QT prolongation. *Toxics* 2021; 9:339. 84. Liang CS, et al. Acute renal failure after paliperidone overdose: a case report. *J Clin Psychopharmacol* 2012; 32:128. 85. Lapid MI, et al. Acute dystonia associated with paliperidone overdose. *Psychosomatics* 2011; 52:291-294. 86. Gomez-Criado MS, et al. Ziprasidone

overdose: cases recorded in the database of Pfizer-Spain and literature review. *Pharmacotherapy* 2005; 25:1660–1665. 87. Arbuck DM. 12,800-mg ziprasidone overdose without significant ECG changes. *Gen Hosp Psychiatry* 2005; 27:222–223. 88. Insa Gomez FJ, et al. Ziprasidone overdose: cardiac safety. *Actas Esp Psiquiatr* 2005; 33:398–400. 89. Klein-Schwartz W, et al. Prospective observational multi-poison center study of ziprasidone exposures. *Clin Toxicol (Phila)* 2007; 45:782–786. 90. Tan HH, et al. A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. *Am J Emerg Med* 2009; 27:607–616. 91. Alipour A, et al. Torsade de pointes after ziprasidone overdose with coingestants. *J Clin Psychopharmacol* 2010; 30:76–77.

920 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 13 92. Spiller HA. Management of carbamazepine overdose. *Pediatr Emerg Care* 2001; 17:452–456. 93. Schmidt S, et al. Signs and symptoms of carbamazepine overdose. *J Neurol* 1995; 242:169–173. 94. Pap C, et al. Severe carbamazepine overdose associated with shock, repeated seizures and extreme high serum concentrations treated by extended intermittent hemodiafiltration. 42nd International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 24–27 May 2022, Tallinn, Estonia. *Clin Toxicol* 2022; 60:abstract 145. 95. Alabi A, et al. Safety profile of lamotrigine in overdose. *Ther Adv Psychopharmacol* 2016; 6:369–381. 96. Alyahya B, et al. Acute lamotrigine overdose: a systematic review of published adult and pediatric cases. *Clin Toxicol (Phila)* 2018; 56:81–89. 97. Tuohy K, et al. Acute lithium intoxication. *Dial Transplant* 2003; 32:478–481. 98. Chen KP, et al. Implication of serum concentration monitoring in patients with lithium intoxication. *Psychiatry Clin Neurosci* 2004; 58:25–29. 99. Offerman SR, et al. Hospitalized lithium overdose cases reported to the California Poison Control System. *Clin Toxicol (Phila)* 2010; 48:443–448. 100. Ferrey AE, et al. Relative toxicity of mood stabilisers and antipsychotics: case fatality and fatal toxicity associated with self-poisoning. *BMC Psychiatry* 2018; 18:399. 101. Isbister GK, et al. Valproate overdose: a comparative cohort study of self poisonings. *Br J Clin Pharmacol* 2003; 55:398–404. 102. Spiller HA, et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. *J Toxicol Clin Toxicol* 2000; 38:755–760. 103. Sztajnkrzycki MD. Valproic acid toxicity: overview and management. *J Toxicol Clin Toxicol* 2002; 40:789–801. 104. Eyer F, et al. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. *J Clin Psychopharmacol* 2005; 25:376–380. 105. Robinson P, et al. Severe hypothermia in association with sodium valproate overdose. *NZ Med J* 2005; 118:U1681. 106. Reith DM, et al. Comparison of the fatal toxicity index of zopiclone with benzodiazepines. *J Toxicol Clin Toxicol* 2003; 41:975–980. 107. Isbister GK, et al. Alprazolam is relatively more toxic than other benzodiazepines in overdose. *Br J Clin Pharmacol* 2004; 58:88–95. 108. Kleinman RA, et al. Benzodiazepine-involved overdose deaths in the USA: 2000–2019. *J Gen Intern Med* 2022; 37:2103–2109. 109. Gable RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. *Addiction* 2004; 99:686–696. 110. Caplehorn JR, et al. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. *Aust NZ J Public Health* 2002; 26:358–362. 111. Martindale Pharma an Ethypharm Group Company. Summary of product characteristics. Methadone 5mg tablets. 2023; (last accessed August 2024) <https://www.medicines.org.uk/emc/product/11838/smpc>. 112. Spiller HA, et al. Toxicity from modafinil ingestion. *Clin Toxicol (Phila)* 2009; 47:153–156. 113. Carstairs SD, et al. A retrospective review of suprathreshold modafinil exposures. *J Med Toxicol* 2010; 6:307–310. 114. Russell J, et al. Retrospective assessment of toxicity following exposure to Orexin pathway modulators modafinil and suvorexant. *Toxicol Commun* 2019; 3:33–36. 115. Bioprojet UK Limited. Summary of product characteristics. Wakix 18 mg film-coated tablets (pitolisant). 2023;

<https://www.medicines.org.uk/emc/product/14454/smpc>. 116. Miljevic C, et al. A case of pregabalin intoxication. *Psychiatriki* 2012; 23:162–165. 117. Wood DM, et al. Significant pregabalin toxicity managed with supportive care alone. *J Med Toxicol* 2010; 6:435–437. 118. Kriikku P, et al. Pregabalin and gabapentin in non-opioid poisoning deaths. *Forensic Sci Int* 2021; 324:110830. 119. Trautman W, et al. Orexin antagonist overdose should not keep you up at night: mild toxicity in a large suvorexant overdose. *Clinical Toxicology* 2023; 61 Suppl 2: abstract 205. <http://doi.org/10.1080/15563650.2023.2233835>. 120. Gock SB, et al. Acute zolpidem overdose – report of two cases. *J Anal Toxicol* 1999; 23:559–562. 121. Garnier R, et al. Acute zolpidem poisoning – analysis of 344 cases. *J Toxicol Clin Toxicol* 1994; 32:391–404. 122. De Donatis D, et al. Extremely high-dosage zolpidem poisoning with favorable outcome. *J Clin Psychopharmacol* 2021; 41:222–223. 123. Pounder D, et al. Zopiclone poisoning. *J Anal Toxicol* 1996; 20:273–274. 124. Bramness JG, et al. Fatal overdose of zopiclone in an elderly woman with bronchogenic carcinoma. *J Forensic Sci* 2001; 46:1247–1249.

Revision #1

Created 2026-01-04 20:18:22 UTC by Omar Ayman

Updated 2026-01-04 20:18:22 UTC by Omar Ayman